ProCE Banner Activity

SWOG S1304: Low- vs High-Dose Carfilzomib + Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Slideset Download
Conference Coverage
Twice-weekly 56-mg/m2 carfilzomib showed similar PFS and OS but higher VGPR rate vs 27-mg/m2 carfilzomib in patients with relapsed/refractory multiple myeloma.

Released: June 11, 2018

Expiration: June 10, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Astellas Text

AstraZeneca

Celgene

Eisai

Genentech TEXT Only

Janssen

Merck Oncology

Seagen